ABSTRACT
As a progressive chronic disease,age-related macular degeneration (AMD) is the leading cause of blindness worldwide.However,current therapy for AM D shows a dramatic breakthrough.More and more patients with AMD undergo intravitreous injection of anti-vascular endothelial growth factor A (VEGF-A) regimen,which has been demonstrated a beneficial therapeutic treatment to improve visual acuity in a short period.The long-term outcomes have come into focus considering prolonged treatment cycle and follow-up period.The long-term outcomes and safety of anti VEGF-A will be reviewed in this article contributing to investigate the causes influencing prognosis of visual acuity after anti VEGF-A treatment.
ABSTRACT
Angiogenidiseaseof the retinare the common reasonof several visual loss.Vasculaendothelial growth facto(VEGF) playan importanrole in pathologiangiogenesis.In recenyears,the developmenof anti-VEGF therapiehatransformed the prognosiof these conditions.The treatmenof angiogenidisease had entered an erof anti-VEGF therapy,especially in the treatmenof choroidal neovascularization (CNV) caused by age-related maculadegeneration (AMD).Abreakthrough,anti-VEGF therapy changethe photodynamitherapy (PDT) based weAMD (wAMD) treatmenmode.In thipaper,we describe thaeven though relegated to background,PDstill haclinical therapeutivalue fospecial circumstanceand certain type of CNV lesion,awell ain certain retindisease.